| 25.99 -0.84 (-3.13%) | 05-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 34.09 | 1-year : | 39.82 |
| Resists | First : | 29.19 | Second : | 34.09 |
| Pivot price | 25.8  |
|||
| Supports | First : | 25.05 | Second : | 22.5 |
| MAs | MA(5) : | 25.6 |
MA(20) : | 25.45 |
| MA(100) : | 16.18 |
MA(250) : | 20.12 |
|
| MACD | MACD : | 0.8 |
Signal : | 1 |
| %K %D | K(14,3) : | 53.9 |
D(3) : | 47 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 39.59 | Low : | 7.38 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VTVT ] has closed below upper band by 46.7%. Bollinger Bands are 12.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.05 - 26.18 | 26.18 - 26.26 |
| Low: | 24.98 - 25.16 | 25.16 - 25.27 |
| Close: | 25.74 - 26 | 26 - 26.17 |
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Fri, 10 May 2024
VTv Therapeutics: Q1 Earnings Snapshot - Middletown Press
Fri, 10 May 2024
vTv Therapeutics Crashes on Alzheimer's Drug Study Failure - Yahoo Movies UK
Fri, 10 May 2024
VTv Therapeutics: Q1 Earnings Snapshot - Houston Chronicle
Thu, 09 May 2024
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update - Yahoo Finance
Wed, 13 Mar 2024
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewswire
Wed, 13 Mar 2024
VTv Therapeutics: Q4 Earnings Snapshot - Quartz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 38.8 (%) |
| Held by Institutions | 16 (%) |
| Shares Short | 29 (K) |
| Shares Short P.Month | 57 (K) |
| EPS | -9.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -11.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -72.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -2.68 |
| PEG Ratio | 0 |
| Price to Book value | -2.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|